PolyTherics, founded in 2002, has focused on technology development in the area of biomedical polymers for therapeutic applications. The most advanced of its techniques, site-specific PEGylation or TheraPEG ™, is being exploited in partnership with companies developing biopharmaceuticals. PolyTherics is also committed to developing its own pipeline of optimised clinical candidates.